Ulcerative Colitis Clinical Trials in Chicago, Illinois

11 studies are recruiting for ulcerative colitis in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

   Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how Risankizumab moves through the body as well as how safe and effective it is in treating pediatric participants …

   Stage

   Phase 3

   Ages

   2 to 17

   Site

   University of Chicago Medical Center /ID# 271588, Chicago, Illinois

   Locations

   64 in total

   Run by

   AbbVie

   See if you can join NCT07071519 on ClinicalTrials.gov

2. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

   This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   52 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03816345 on ClinicalTrials.gov

3. LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

   The main purpose of the study is to evaluate the effectiveness and safety of LY4268989 when given with mirikizumab compared to mirikizumab alone in adult participants with moderately to severely active ulcerative colitis (UC). Study participation will last approximately 118 weeks, including 104 wee…

   Stage

   Phase 2

   Ages

   18 to 80

   Site

   Northwestern University, Chicago, Illinois

   Locations

   147 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07186101 on ClinicalTrials.gov

4. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

   The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation …

   Stage

   Phase 3

   Ages

   18 to 70

   Site

   Rush University Medical Center, Chicago, Illinois

   Locations

   187 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06937086 on ClinicalTrials.gov

5. A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

   The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerative colitis for whom prior treatment with conventional and/or advanced therapies has failed.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Chicago Medical Center, Chicago, Illinois

   Locations

   106 in total

   Run by

   Genentech, Inc.

   See if you can join NCT06979336 on ClinicalTrials.gov

6. A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

   This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is to assess the efficacy and safety of multiple interventions following intravenous (IV) induction and subcutaneous (SC) m…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Site 038, Chicago, Illinois

   Locations

   267 in total

   Run by

   Spyre Therapeutics, Inc.

   See if you can join NCT07012395 on ClinicalTrials.gov

7. An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

   This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis (UC). Study details include: The study duration may be up to 35 weeks wi…

   Stage

   Phase 3

   Ages

   16 to 80

   Site

   Rush University Medical Center - Site Number: 8400015, Chicago, Illinois

   Locations

   219 in total

   Run by

   Sanofi

   See if you can join NCT07184996 on ClinicalTrials.gov

8. A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

   The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC). Another aim is to learn about treatment with Vedolizumab alone after the double treatment. All participants wi…

   Stage

   Phase 4

   Ages

   18 to 65

   Site

   University of Chicago Medicine, Chicago, Illinois

   Locations

   46 in total

   Run by

   Takeda

   See if you can join NCT06095128 on ClinicalTrials.gov

9. Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

   The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ul…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Chicago Medicine, Chicago, Illinois

   Locations

   24 in total

   Run by

   Mayo Clinic

   See if you can join NCT05230173 on ClinicalTrials.gov

10. A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

    The main purpose of this study is to determine the safety and efficacy of eltrekibart and mirikizumab in adult participants with moderately to severely active ulcerative colitis (UC).

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    Northwestern University, Chicago, Illinois

    Locations

    207 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06598943 on ClinicalTrials.gov

11. A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

    The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to < 18 years of age). Participants who will complete the total 52-week treatment period will ha…

    Stage

    Phase 2

    Ages

    12 to 17

    Site

    University of Chicago Medical Center, Chicago, Illinois

    Locations

    45 in total

    Run by

    Pfizer

    See if you can join NCT05287126 on ClinicalTrials.gov